Marzolini, C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back D, and Khoo S. Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions, Ann Intern Med 2022; 175: 744-46
https://pubmed.ncbi.nlm.nih.gov/35226530/
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S.Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid® ) and comedications.Clin Pharmacol Ther. 2022 May 14 Online ahead of print
https://pubmed.ncbi.nlm.nih.gov/35567754/
[CYP3A inhibitors as a pharmacokinetic enhancer: pros and cons of drug interactions; in Dutch].
Burger DM, van Erp PH, Ter Heine R. Ned Tijdschr Geneeskd. 2022 May 31;166:D6817.
https://www.ntvg.nl/artikelen/cyp3a-remmers-als-farmacokinetische-hulpstof